Clin Gastroenterology H: STAT6 variants are associated with recurrence of eosinophilic esophagitis in patients receiving long-term proton pump inhibitor therapy

Currently, eosinophilic esophagitis (EoE) clinical consensus guidelines support proton pump inhibitor (PPI) drugs as the main treatment for EoE in children and adults
.

Researchers conducted a prospective longitudinal cohort study of children aged 2 to 16 who met the diagnostic criteria of EoE (≥15 eosinophils/high power field [eos/hpf]), and measured 2 mg/kg/d for 8 weeks EoE patients who responded to treatment reduced their dose to 1 mg/kg/d PPI for maintenance treatment for 1 year.
At this time, biopsy specimens were collected through endoscopy
.

Among 73 patients who received 1 mg/kg/d PPI maintenance treatment for 1 year, 13 patients (18%) had eos/hpf of 6 to 14, and 36 patients (49%) had eos/hpf of 5 or more Few, 24 patients (33%) had disease recurrence to EoE (≥15 eos/hpf)
.

Figure: The relationship between gene mutation and EoE recurrence

This study confirmed that children with EoE patients who initially responded to PPI treatment and carried STAT6 variants rs324011, rs167769, or rs12368672 had an increased risk of recurrence after 1 year of PPI maintenance
.

Original source:

Edward B.